Diquafosol DE 089, diquafosol tetrasodium, INS 365, INS 365 ophthalmic, INS 365 respiratory, KPY 998

Drugs in R and D

Volumn 4, Issue 6, 2003, Pages 359-362

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DE 089; DIQUAFOSOL; EYE DROPS; INS 365 OPHTHALMIC; INS 365 RESPIRATORY; KPY 998; MUCOLYTIC AGENT; UNCLASSIFIED DRUG; URIDINE TRIPHOSPHATE;

CLINICAL TRIAL; COUGHING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRY EYE; HUMAN; MUCOCILIARY CLEARANCE; NONHUMAN; NOSE CONGESTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT MUCOSA; REVIEW; WHEEZING;

ADMINISTRATION, INHALATION; CLINICAL TRIALS; DRY EYE SYNDROMES; EXPECTORANTS; HUMANS; OPHTHALMIC SOLUTIONS; POLYPHOSPHATES; RESPIRATORY TRACT DISEASES; URACIL NUCLEOTIDES;

EID: 0242690311     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200304060-00005     Document Type: Review

References (10)

1. Inspire Pharmaceuticals. Inspire Pharmaceuticals Announces FDA Acceptance Of Diquafosol NDA for Filing. Media Release: 9 Sep 2003. Available from URL: http://www.inspirepharm.com
2. Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals' Diquafosol NDA Granted Priority Review by the FDA. Media Release: 31 Jul 2003. Available from URL: http://www.nrpeuro.com
3. Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals, Inc. reports positive results for novel therapeutic for dry eye disease. Media Release: [2 pages], 11 May 1999
4. Evans R, Johnson F, Kellerman D, et al. Aerosolized INS365 for COPD: enhanced deposition and clearance using the AERx delivery system. American Journal of Respiratory and Critical Care Medicine 161 (Suppl.): 815, Part 2, Mar 2000
5. Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals reports positive phase I results for INS365; announces new clinical collaboration with cystic fibrosis foundation. Media Release: [2 pages], 17 Oct 1998
6. Kellerman DJ, Bennett WD, Zeman KL, et al. Dose response relationship of the P2Y2 agonist INS365 on mucociliary clearance in smokers. Journal of Allergy and Clinical Immunology 107 (Abstr. Suppl.): 164-165, Feb 2001
7. Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals, Inc. presents positive phase II data for INS365 ophthalmic for dry eye, and launches first phase I/II clinical trial for INS37217 ophthalmic for retinal detachment. Media Release: [3 pages], 3 May 2001. Available from URL: http://www.inspirepharm.com
8. Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals Announces Results of Second Phase III Trial of INS365 Ophthalmic for The Treatment of Dry Eye. Media Release: 18 Jun 2002. Available from URL: http://www.inspirepharm.com
9. Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals Announces Timing of Dry Eye NDA Based on Pre-NDA Meeting with the FDA - Also Provides Guidance on 2003 Revenues. Media Release: 7 Jan 2003. Available from URL: http://www.inspirepharm.com
10. Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals Announces Results of Phase IIIb Study in Dry Eye. Media Release : 13 Aug 2003. Available from URL: http://www.inspirepharm.com